Plus Therapeutics Announces New Employment Inducement Grants
17 mai 2024 17h00 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Announces New Employment Inducement Grants
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
15 mai 2024 16h15 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024
13 mai 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial
09 mai 2024 11h29 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
08 mai 2024 17h35 HE
|
Plus Therapeutics Inc.
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
Plus Therapeutics Announces Private Placement Financing of up to $18 Million
06 mai 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Announces Private Placement Financing of up to $18 Million
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
22 avr. 2024 07h00 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team
09 avr. 2024 07h00 HE
|
Plus Therapeutics Inc.
The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic commitments but will greatly contribute to Plus’...
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
27 mars 2024 08h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
25 mars 2024 08h00 HE
|
Plus Therapeutics Inc.
Plus’ CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and melanoma cancer cells in the leptomeninges CSF-01 testing is used as an...